相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus
Paula Debroy et al.
CLINICAL INFECTIOUS DISEASES (2021)
Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada
Peter F. Rebeiro et al.
CLINICAL INFECTIOUS DISEASES (2021)
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul E. Sax et al.
CLINICAL INFECTIOUS DISEASES (2020)
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter et al.
GASTROENTEROLOGY (2020)
Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus
Adriana Cervo et al.
CLINICAL INFECTIOUS DISEASES (2020)
The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes
Jennifer Gorwood et al.
CLINICAL INFECTIOUS DISEASES (2020)
Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study
Ditte Marie Kirkegaard-Klitbo et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
Kassem Bourgi et al.
Journal of the International AIDS Society (2020)
Comorbidities in Older Persons with Controlled HIV Infection: Correlations with Frailty Index Subtypes
Jacqueline M. McMillan et al.
AIDS PATIENT CARE AND STDS (2020)
Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study
Axel Ursenbach et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients
Michael Praktiknjo et al.
LIVER INTERNATIONAL (2019)
Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication
David Chromy et al.
AIDS PATIENT CARE AND STDS (2019)
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease
Leonardo Calza et al.
INFECTIOUS DISEASES (2019)
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castera et al.
GASTROENTEROLOGY (2019)
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients
Leonardo Calza et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Adipose cell size: importance in health and disease
Karin G. Stenkula et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2018)
Adipocytes impair efficacy of antiretroviral therapy
Jacob Couturier et al.
ANTIVIRAL RESEARCH (2018)
Energy metabolism of white adipose tissue and insulin resistance in humans
Kalman Bodis et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2018)
Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system
Michael A. Horberg et al.
HIV CLINICAL TRIALS (2018)
The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection
Jordan E. Lake
CURRENT HIV/AIDS REPORTS (2017)
Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults
Jennifer C. Price et al.
AIDS (2017)
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease
Juan Macias et al.
CLINICAL INFECTIOUS DISEASES (2017)
Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients
Elise Vuille-Lessard et al.
AIDS (2016)
Liver fibrosis and fatty liver in Asian HIV-infected patients
G. Lui et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction
Sofia Laforest et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2015)
Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
Jordan E. Lake et al.
OPEN FORUM INFECTIOUS DISEASES (2015)
Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study
Jennifer C. Price et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial
J. E. Lake et al.
HIV MEDICINE (2014)
Adipocyte morphology and implications for metabolic derangements in acquired obesity
S. Heinonen et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
Esteban Martinez et al.
AIDS (2012)
Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy
Adrian Curran et al.
AIDS (2012)
A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy
Jordan E. Lake et al.
AIDS PATIENT CARE AND STDS (2012)
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Anna Kotronen et al.
GASTROENTEROLOGY (2009)
Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package
D. Stefan et al.
MEASUREMENT SCIENCE AND TECHNOLOGY (2009)
HIV-1 Infection and the PPAR gamma-Dependent Control of Adipose Tissue Physiology
Marta Giralt et al.
PPAR RESEARCH (2009)
Fatty liver - A novel component of the metabolic syndrome
Anna Kotronen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Relationship between adipocyte size and adipokine expression and secretion
Thomas Skurk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
分享论文
